# Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients

> **NCT03053167** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 100 (estimated)

## Conditions studied

- ColoRectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Raltitrexed

## Key facts

- **NCT ID:** NCT03053167
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-02-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053167, "Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03053167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*